Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | AHCY | P23526 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8960068 | 0.91 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL239127 | 0.91 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL1401951 | 0.91 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL12003121 | 0.91 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL3714471 | 0.91 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL1401952 | 0.91 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL242481 | 0.85 | LMNA (0.40) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL13177712 | 0.82 | HTR2C (0.38) | HTR2CHTR2BTMIGD3ADORA3ADORA1 | |
| SCHEMBL13211904 | 0.81 | LMNA (0.43) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL4349807 | 0.81 | ADORA3 (0.33) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281126-A1 | Organic Compounds | NOVARTIS AG | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281126-A1 | Organic Compounds | CYP3A43, CYP3A4, CYP2C19 | LMNA 3049/4885TP53 1533/4885ALDH1A1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.